The Impact of Index Rebalancing London Stock Exchange subsidiary FTSE Russell completed its annual reconstitution effective ...

Regeneron Pharmaceuticals (REGN) reported interim results from a mid-stage trial testing combinations of semaglutide with experimental antibodies, trevogrumab and garetosmab, for treating obesity.

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data? What to know.

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for ...

Regeneron Pharmaceuticals announced its sixth inclusion in the Dow Jones Sustainability World Index, reflecting strong corporate responsibility and governance.

We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

The DNA testing company would sell for a fraction of its peak valuation of $6 billion to a biotech aiming to use its data troves for drug research.

Regeneron has steadily grown into a massive presence in the Albany region, shaping everything from real estate to workforce. And now it's expanding into Albany and Saratoga counties.

Regeneron Pharmaceuticals agreed to buy DNA testing company 23andMe in a bankruptcy court auction, the company said Monday.

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing capacity and ...